1.Effect of chemotherapy on the expression of CD8 + CD28-T cells in peripheral blood of non-small-cell lung cancer patients
Guanzhong LIANG ; Yanfeng WANG ; Fucai HAN
Journal of International Oncology 2016;43(5):335-339
Objective To observe the expression of CD8 + CD28-T cells in the peripheral blood of non-small-cell lung cancer (NSCLC) patients,and to investigate the effect of chemotherapy on CD8 + CD28-T cells expression and its clinical significance.Methods Flow cytometry was used to evaluate the level of CD8 + CD28-T cells in peripheral blood of 70 untreated NSCLC patients and 60 healthy controls.The association between CD8 + CD28-T cells and the clinical features was analyzed.We also investigated the changes of CD8 + CD28-T cells in 30 NSCLC patients who received chemotherapy by GP (gemcitabine,cisplatin) and NP (navelbine,cisplatin).Results The proportion of CD8 + CD28-T cells in lung cancer group was significantly higher than that in healthy group (59.003% ± 15.329% vs.41.036% ± 15.435%,t =35.904,P =0.001).No correlation was found between CD8 + CD28-T cells expression and the gender (F =1.374,P =0.697),pathological pattern (F =0.779,P =0.509) and clinical stage (F =0.070,P =0.933).But CD8 + CD28-T cells expression was correlated with the age (F =15.038,P =0.001).The level of CD8 + CD28-T cells after NP chemotherapy was lower than that before chemotherapy (55.293% ± 14.637% vs.58.793% ± 12.510%,t =2.017,P =0.044).And the level of CD8 + CD28-T cells after GP chemotherapy was lower than that before chemotherapy (54.127% ± 13.924% vs.60.700% ± 16.401%,t =3.007,P =0.009).Conclusion CD8 + CD28-T cells express highly in NSCLC patients peripheral blood.Chemotherapy down-regulates CD8 + CD28-T cells expression,which provides a new reference for combination with chemotherapy and immunotherapy in NSCLC patients.
2.Clinical research of drug-resistant gene detection combined with adenosine triphosphate-tumor chemosensitivity assay for guiding the second-line chemotherapy of lung squamous cell cancer
Binbin SHAN ; Weihua YANG ; Yanfeng XI ; Fucai HAN ; Songyan HAN ; Quanmao ZHANG ; Yanhong BAI
Cancer Research and Clinic 2016;28(7):447-451
Objective To investigate the significance of resistant gene detection combined with adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) in the second-line chemotherapy of lung squamous cell cancer, and to provide a reference for clinical treatment. Methods 150 patients with lung squamous cell cancer diagnosed by histopathology or cytology and with the disease progressed after NP regime chemotherapy were enrolled. The mRNA expressions of excision repair cross complementation 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) were detected by RT-PCR, and ATP-TCA was carried out. After detected by RT-PCR and ATP-TCA, the patients who were sensitive to gemcitabine plus cisplatin (GP) accepted the second-line systemic chemotherapy with GP regimen, and the others who were not sensitive to GP regimen or whose results of gene detection and ATP-TCA were on the contrary took the second-line chemotherapy regimens with docetaxel plus cisplatin (DP). Both groups accepted 2-4 cycles of systemic chemotherapy. The chest CT was followed up, and the response rate (RR), progression-free survival (PFS) and median survival time (MST) were investigated. Results The RR of GP group was 36.2 % (17/47), while the DP group was 28.1 % (26/92), and the difference was statistically significant (χ2= 4.274, P< 0.05). The media PFS of GP group and DP group were 4.2 months (95%CI 3.485-5.348 months) and 3.6 months (95 %CI 2.685-4.648 months), respectively, and the difference was statistically significant (P<0.05). The MST of GP group and DP group were 9.6 months (95 %CI 8.283-10.637 months) and 8.9 months (95 %CI 7.384-9.648 months), respectively, and there was no statistically significant difference (P> 0.05). Conclusion The resistance gene detection combined with ATP-TCA have certain guiding significance on the second-line chemotherapy for advanced lung squamous cell cancer.
3.Does Limited Tourniquet Usage in Primary Total Knee Arthroplasty Result in Better Functional Outcomes?
Gurpal SINGH ; Fucai HAN ; Ratnakar Rao KAKI ; Liang SHEN ; Saminathan Suresh NATHAN
Annals of the Academy of Medicine, Singapore 2015;44(8):302-306
Aged
;
Arthroplasty, Replacement, Knee
;
adverse effects
;
methods
;
Case-Control Studies
;
Female
;
Follow-Up Studies
;
Humans
;
Incidence
;
Intraoperative Care
;
instrumentation
;
methods
;
Male
;
Middle Aged
;
Osteoarthritis, Knee
;
surgery
;
Postoperative Complications
;
diagnosis
;
epidemiology
;
etiology
;
prevention & control
;
Recovery of Function
;
Risk Assessment
;
Singapore
;
epidemiology
;
Tourniquets
;
adverse effects
;
Treatment Outcome
4.Intramedullary compression device for proximal ulna fracture.
Choon Chiet HONG ; Fucai HAN ; Joshua DECRUZ ; Vinodhkumar PANNIRSELVAM ; Diarmuid MURPHY
Singapore medical journal 2015;56(2):e17-20
Proximal ulna fractures account for 20% of all proximal forearm fractures. Many treatment options are available for such fractures, such as cast immobilisation, plate and screw fixation, tension band wiring and intramedullary screw fixation, depending on the fracture pattern. Due to the subcutaneous nature of the proximal forearm, it is vulnerable to open injuries over the dorsal aspect of the proximal ulna. This may in turn prove challenging, as it is critical to obtain adequate soft tissue coverage to reduce the risk of implant exposure and bony infections. We herein describe a patient with a Gustillo III-B open fracture of the proximal ulna, treated with minimally invasive intramedullary screw fixation using a 6.0-mm cannulated headless titanium compression screw (FusiFIX, Péronnas, France).
Adult
;
Bone Screws
;
Forearm Injuries
;
surgery
;
Fracture Fixation, Internal
;
methods
;
Fracture Fixation, Intramedullary
;
methods
;
Fracture Healing
;
Fractures, Open
;
surgery
;
Humans
;
Male
;
Radius Fractures
;
Range of Motion, Articular
;
Titanium
;
Ulna Fractures
;
surgery
5.Expression and clinical significance of IL-17-producing CD4+ T and IL-17-producing CD8+ T cells in the peripheral blood of lung cancer patients
Jianhong HUANG ; Yanfeng WANG ; Jinfang ZHAI ; Li SHI ; Wen SU ; Fucai HAN
Cancer Research and Clinic 2013;25(7):463-465
Objective To investigate the expression and clinical significance of Th17 and Tc17 cells in peripheral blood of lung cancer patients.Methods The percentages of Th17 cells and Tc17 cells in 60 lung cancer patients and 40 healthy controls were evaluated by flow cytometry analysis (FCM).Results The percentages of Th17 cells [(1.795±0.623) %] and Te17 cells [(0.865±0.357) %] in lung cancer group were significandy higher than those in controls [(1.405±0.256) %,(0.640 ±0.204) %],(t =28.944,P < 0.001,t =14.051,P < 0.001).Furthermore,there was a positive correlation between Th17 cells and Tc17 cells in the two groups (lung cancer group r =0.770,P < 0.05,control group r =0.532,P < 0.05).The percentages of Th17 cells and Tc17 cells were closely associated with clinical stage (F =4.882,P =0.011,F =3.633,P =0.033),but not connected with pathological types (P > 0.05,P > 0.05).Conclusion The overexpression of Th17 and Tc17 may be involved in the occurrence and development of lung cancer,which can be used as new indicators for immunologic function of lung cancer patients,and provide a reference in monitoring the disease.
6.Expression and clinical significance of CD+8 CD-28 and CD+4CDhigh25 CDlow127 regulatory T cells in peripheral blood of lung cancer patients
Guanzhong LIANG ; Yanfeng WANG ; Silu YANG ; Wen SU ; Fucai HAN
Cancer Research and Clinic 2012;24(6):376-379
Objective To observe the changes of CD+8CD+28,CD+8CD-28 and CD+4CDhigh25CDlow127 regulate T (Treg)cellsin peripheral blood of lung cancer patients,and to analyze the correlation between CD+8CD-28 and CD+4CDhigh25CDlow127 Treg cells to reveal the role and clinical significance of them in lung cancer patients.Methods Flow cytometry was applied to evaluate the level of CD+8CD+28,CD+8CD-28 and CD+4CDhigh25CDlow127 Treg cells in peripheral blood of 60 untreated lung cancer patients and 60 healthy controls group.The association of each term with clinical features was analyzed.Results The percentage of CD+8CD-28 and CD+4CDhigh25CDlow127 Treg cells in lung cancer group[(58.430:15.749) %,(7.365±2.025) %]was significantly higher than those in healthy group [(41.057±15.436)%,(6.648±1.669)%,(t=6.102,P<0.05;t=2.115,P<0.05)],while the percentage of CD+8CD+28cells is lower(41.570±15.739)% than that in healthy group[(58.700±15.298)%,(t=-6.043,P<0.05)].No close associations were found between three index and gender,age,and biological characteristics.With the increase of TNM stage,The percentage of CD+4CDhigh25 CDlow127 Treg cells increased gradually,which was remarkably higher in patients rith stage Ⅳ than that with stage ⅢA(t=-3.898,P<0.05).The percentage of CD+4CDhigh25 CDlow127 Tregcells was uncorrelated with CD+8CD-28 cells(r=-0.169,P>0.05).Conclusion The higher percentage of CD+8CD-28 and CD+4CDhigh25 CDlow127 Treg cells,the lower percentage of CD+8CD+28 cells may be the important reasons of immune suppression in lung cancer patients.Though there is no correlation between CD+8CD-28 and CD+4CDhigh25 CDlow127 Treg cells,it is may be helpful to understand immunologic function and it may look for more specific therapy and provide a new reference in the prognosis of lung cancer.
7.Expression and clinical significance of CD+8 natural killer T cell receptors NKG2D and NKG2A in peripheral blood of patients with lung cancer
Ni CHENG ; Yanfeng WANG ; Zhihua TIAN ; Wen SU ; Fucai HAN
Cancer Research and Clinic 2011;23(5):321-323,327
Objective The aim of this study is to investigate CD+8 natural killer T cell receptors NKG2D and NKG2A expression in peripheral blood of patients with lung cancer and discuss the relation between imbalance expression of NKG2A and NKG2D and tumor immune escape. Methods Flow cytometry was used to determine the percentage of NKG2D and NKG2A-expressing of CD+8 NKT cells in peripheral blood of 95 untreated lung cancer patients and 50 healthy controls. Results NKG2D was lower expressed on CD+8 NKT in lung cancer, the level of NKG2D in patients (77.07±5.77) % was significantly lower than that in the controls (84.13±4.49) % (t =8.14, P <0.05). In the TNM stage, the level of NKG2D in patients of Ⅰ-ⅢA, ⅢB, Ⅳ stage were (81.07±5.02) %, (76.95 ±4.70)%, (72.80±5.16) %, respectively, the level of NKG2D was significantly decreased in order (F =18.74, P <0.05). NKG2A was expressed higher on CD+8 NKT in lung cancer, the level of NKG2A in patients (33.58±8.82) % was significantly higher than that in the controls (25.31 ±8.38) % (t =-5.46, P<0.05). In the TNM stage, the level of NKG2A in patients of Ⅰ - Ⅲ A, ⅢB, Ⅳ stage were (25.10±6.93) %, (33.24±3.76) %, (43.64±6.10) %, respectively, the level of NKG2A was significantly increased in order (F =75.73,P <0.05). Conclusion Imbalance expression of NKG2A and NKG2D may restrain the function of CD+8 NKT cell of lung cancer patients in peripheral blood and that may be one of important factors in tumor immunological escape.
8.Evaluation of the value and safety of transbronchial needle aspiration in the diagnosis of lung cancer
Songyan HAN ; Fucai HAN ; Weihua YANG ; Jinxiu KANG ; Zhijuan GUO ; Tingting GUO ; Yuexiang LIU ; Fang CHANG ; Quanhong WANG
Cancer Research and Clinic 2009;21(6):383-385
Objective To evaluate the value and safety of transbronchial needle aspiration (TBNA) in the diagnosis of lung cancer. Methods The cytologic diagnosis of TBNA in 82 patients with enlarged hilar and/or mediastinal lymphnodes or lesions adjacent to the bronchial wall were analyzed retrospectively. All specimens were detected by the ThinPrep cytologic test. Results There were 43 positive cases in the 82 patients, and the positive rate was 52.4 %. There were 18 SCLCs,11squamous cancers, 9 adenocarcinomas and 5 undefinable cancers, respectively. There were 39 patients with local bronchial wall swelling accompanied with abnormal mucosae. TBNA, douche, brushing and forcep biopsy were applied, and the diagnostic rate was 64.1%, 7.7 %, 25.6 % and 48.7 %, respectively. The total positive rate was 76.9 %. 43 patients with normal mucous membrane only underwent TBNA. 18 cases were positive, and the positive rate was 41.9 %. There was no obvious complication in the 82 patients. Conclusion The technique of TBNA enlarged the inspection scope of bronchoscopy. It has significant meaning to the diagnosis of lung cancer. TBNA was an useful and safe method in clinical application and could be used widely.
9.CD+4 CD+25 regulatory T cells and lung cancer
Cancer Research and Clinic 2009;21(3):205-207
To know CD+4 CD+25 regulatory T cells' s function in tumor immunological regulation and to search for its functionary molecule mechanism by reviewing researches associated with the characteristics of CD+4 CD+25 regulatory T cells surface molecules and the expression of CD+4 CD+25 regulatory T cells in the peripheral blood and tissues.
10.Research on relevance of sMICA and lung cancer
Jing LIANG ; Fucai HAN ; Lijnan QIAO ; Binbin SHAN
Cancer Research and Clinic 2008;20(9):600-603
Objectives To study the clinical diagnostic value of soluble major histocompatibility complex class Ⅰ-related chain A(sMICA) and analyse the relationship of tumor biologic characteristics and sMICA in lung cancer. Methods The experimental level of sMICA was determined by ELISA in 116 lung cancer patients. The level of serum CEA, NSE, CA-199, CYFRA-211, SCC, ProGRP were determined by ELISA only in 91 lung cancer patients without any therapy. The level of sMICA in 50 normal persons was regarded as control group. Results The level of sMICA in lung cancer patients was significantly higher than that in control group (P<0.001); When sMICA cut-off was set as 240.5 ng/L, the sensitivity for the detection of lung cancer was 90.1%, the speciality was 46.9%. The positive rate of sMICA was significantly higher than that of CEA, NSE, CA-199, CYFRA-211, SCC, ProGRP(P<0.001 respectively); The level of sMICA in lung cancer patients with CR and PR after treatment were lower than that before treatment(P<0.05). The level of sMICA in lung cancer patients with relapse was higher than patients without any treatment (P<0.001). Conclusion SMICA may be a potential marker for diagnosing lung cancer with high sensitivity and speciality. It is associated with tumor progression and distant metastasis and may be helpful in the evaluation of diagnosis for lung cancer.

Result Analysis
Print
Save
E-mail